Mediolanum International Funds Ltd Buys Shares of 14,339 argenex SE $ARGX

Mediolanum International Funds Ltd purchased a new stake in shares of argenex SE (NASDAQ:ARGX) during the third quarter, Holdings Channel reports. The institutional investor purchased 14,339 shares of the company’s stock, valued at approximately $10,310,000.

Other hedge funds have also recently bought and sold shares of the company. AQR Capital Management LLC grew its stake in argenex by 32.1% during the 1st quarter. AQR Capital Management LLC now owns 502 shares of the company’s stock valued at $297,000 after acquiring an additional 122 shares in the last quarter. NewEdge Advisors LLC increased its stake in argenex by 5,962.5% in the 1st quarter. NewEdge Advisors LLC now owns 1,455 shares of the company’s stock valued at $862,000 after buying an additional 1,431 shares during the period. Focus Partners Wealth lifted its position in argenex by 22.3% in the 1st quarter. Focus Partners Wealth now owns 400 shares of the company’s stock worth $237,000 after buying an additional 73 shares in the last quarter. Geneos Wealth Management Inc. boosted its stake in shares of argenex by 550.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock valued at $69,000 after buying an additional 99 shares during the period. Finally, Janney Montgomery Scott LLC grew its holdings in shares of argenex by 2.6% during the 2nd quarter. Janney Montgomery Scott LLC now owns 1,171 shares of the company’s stock valued at $645,000 after acquiring an additional 30 shares in the last quarter. 60.32% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ARGX has been the topic of several research reports. HC Wainwright upped their target price on argenex from $774.00 to $915.00 and gave the stock a “buy” rating in a research report on Friday, October 31st. TD Cowen lifted their target price on shares of argenex from $800.00 to $1,146.00 and gave the stock a “buy” rating in a report on Friday, October 31st. Royal Bank Of Canada raised their price objective on shares of argenex from $860.00 to $925.00 and gave the stock an “outperform” rating in a report on Wednesday, December 17th. JPMorgan Chase & Co. increased their target price on argenex from $925.00 to $1,100.00 and gave the stock an “overweight” rating in a report on Monday, December 8th. Finally, Wolfe Research reissued a “peer perform” rating on shares of argenex in a report on Monday, November 24th. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, argenex currently has an average rating of “Moderate Buy” and a consensus target price of $986.78.

argenex Trading Down 0.9%

Shares of NASDAQ:ARGX opened at $840.50 on Monday. argenex SE has a 1-year low of $510.05 and a 1-year high of $934.62. The business has a 50-day moving average price of $852.12 and a two-hundred day moving average price of $784.39. The stock has a market capitalization of $52.01 billion, a P/E ratio of 36.09, a P/E/G ratio of 0.55 and a beta of 0.37.

argenex (NASDAQ:ARGX) last posted its quarterly earnings data on Thursday, October 30th. The company reported $4.40 EPS for the quarter, topping analysts’ consensus estimates of $4.37 by $0.03. The company had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.07 billion. argenex had a net margin of 41.58% and a return on equity of 29.78%. As a group, equities analysts predict that argenex SE will post 3.13 EPS for the current year.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.